Document:

EX-4.2

 Exhibit 4.2 
  

 
 ZQ|CERT#|COY|CLS|RGSTRY|ACCT#|TRANSTYPE|RUN#|TRANS# COMMON STOCK PAR VALUE $0.0001 COMMON STOCK Certificate
Number ZQ00000000 BLACK DIAMOND THERAPEUTICS, INC. INCORPORATED UNDER THE LAWS OF THE STATE OF DELAWARE Shares 000000 000000 000000 000000 000000 THIS CERTIFIES THAT Mr. Alexander David Sample Mr. Alexander David Sample Mr. Alexander
David Sample Mr. Alexander David Sample Mr. Alexander David Sample SEE REVERSE FOR CERTAIN DEFINITIONS Mr. Alexander David Sample Mr. Alexander David Sample Mr. Alexander David Sample Mr. Alexander David Sample
Mr. Alexander David Sample Mr. Alexander David Sample Mr. Alexander David Sample Mr. Alexander David Sample Mr. Alexander David Sample Mr. Alexander David Sample Mr. MR. Alexander David SAMPLE Sample
Mr. Alexander David &Sample MRS. Mr. Alexander SAMPLE David Sample Mr. Alexander & David Sample Mr. Alexander David Sample Mr. Alexander David Sample Mr. Alexander David Sample Mr Alexander David Sample
Mr. Alexander David Sample CUSIP 09203E 10 5 Mr. Alexander David Sample Mr. Alexander David Sample Mr. Alexander David Sample Mr. Alexander David Sample Mr. Alexander David Sample Mr. Alexander David Sample
Mr. Alexander David Sample Mr. Alexander David Sample Mr. Alexander David Sample Mr. Alexander David Sample Mr. Alexander MR. David Sample SAMPLE Mr. Alexander David Sample &Mr. Alexander MRS. David Sample
SAMPLE Mr. Alexander David Sample Mr. Alexander David Sample Mr. Alexander David Sample Mr. Alexander David Sample Mr. Alexander David Sample Mr. Alexander David Sample Mr. Alexander David Sample Mr. Alexander
David Sample Mr. Alexander David Sample Mr. Alexander David Sample Mr. Alexander David Sample Mr. Alexander David Sample Mr. Alexander David Sample Mr. Alexander David Sample Mr. Alexander David Sample
Mr. Sample Mr. Sample is the owner of 000000 Shares 000000 Shares 000000 Shares 000000 Shares 000000 Shares 000000 Shares 000000 Shares 000000 Shares 000000 Shares 000000 Shares 000000 Shares 000000 Shares 000000 Shares 000000 Shares
000000 Shares 000000 Shares 000000 Shares 000000 Shares 000000 Shares 000000 Shares 000000 Shares 000000 Shares 000000 Shares 000000 Shares 0 THIS CERTIFICATE IS TRANSFERABLE IN 00000 Shares 000000 Shares 000000 Shares 000000 Shares 000000 Shares
000000 Shares 000000 Shares 000000 Shares 00 ZEROâ€^HUNDRED THOUSAND 0000 Shares 000000 Shares 000000 Shares 000000 Shares 000000 Shares 000000 Shares 000000 Shares 000000 Shares 000 CITIES DESIGNATED BY THE TRANSFER 000 Shares 000000
Shares 000000 Shares 000000 Shares 000000 Shares 000000 Shares 000000 Shares 000000 Shares 0000 AGENT, AVAILABLE ONLINE AT 00 Shares 000000 Shares 000000 Shares 000000 Shares 000000 Shares 000000 Shares 000000 Shares 000000 Shares 00000 0 Shares
000000 Shares 000000 Shares 000000 Shares 000000 Shares 000000 Shares 000000 Shares 000000 Shares 000000 ZERO HUNDRED AND ZERO www.computershare.com Shares 000000 Shares 000000 Shares 000000 Shares 000000 Shares 000000 Shares 000000 Shares 000000
Shares 000000 Shares 000000 Shares 000000 Shares 000000 Shares 000000 Shares 000000 Shares 000000 Shares 000000 Shares 000000 Shares 000000 Shares 000000 Shares 000000 Shares 000000 Shares 000000 Shares 000000 Shares 000000 Shares 000000 S
FULLY-PAID AND NON-ASSESSABLE SHARES OF COMMON STOCK OF Black Diamond Therapeutics, Inc. (hereinafter called the “Company”), transferable on the books of the Company in person or by duly authorized
attorney, upon surrender of this Certificate properly endorsed. This Certificate and the shares represented hereby, are issued and shall be held subject to all of the provisions of the Certificate of Incorporation, as amended, and the By-Laws, as amended, of the Company (copies of which are on file with the Company and with the Transfer Agent), to all of which each holder, by acceptance hereof, assents. This Certificate is not valid unless
countersigned and registered by the Transfer Agent and Registrar. Witness the facsimile seal of the Company and the facsimile signatures of its duly authorized officers. President and Chief Executive Officer Chief Financial Officer DATED DD-MMM-YYYY COUNTERSIGNED AND REGISTERED: COMPUTERSHARE TRUST COMPANY, N.A. TRANSFERâ€^AGENT ANDâ€^REGISTRAR, By AUTHORIZEDâ€^SIGNATURE
CUSIP/IDENTIFIER XXXXXX XX X Holder ID XXXXXXXXXX Insurance Value 00.1,000,000 Number of Shares 123456 DTC 12345678901234512345678 PO BOX 505006, Louisville, KY 40233-5006 Certificate Numbers Num/No Denom. Total. MR A SAMPLE 1234567890/1234567890
111 DESIGNATION (IF ANY) 1234567890/1234567890 222 ADD 1 ADD 2 1234567890/1234567890 333 1234567890/1234567890 444 ADD 3 ADD 4 1234567890/1234567890 555 1234567890/1234567890 666 Total Transaction 7 

 

 
 BLACK DIAMOND THERAPEUTICS, INC. THE COMPANY WILL FURNISH WITHOUT CHARGE TO EACH SHAREHOLDER WHO SO REQUESTS, A SUMMARY OF THE POWERS,
DESIGNATIONS, PREFERENCES AND RELATIVE, PARTICIPATING, OPTIONAL OR OTHER SPECIAL RIGHTS OF EACH CLASS OF STOCK OF THE COMPANY AND THE QUALIFICATIONS, LIMITATIONS OR RESTRICTIONS OF SUCH PREFERENCES AND RIGHTS, AND THE VARIATIONS IN RIGHTS,
PREFERENCES AND LIMITATIONS DETERMINED FOR EACH SERIES, WHICH ARE FIXED BY THE CERTIFICATE OF INCORPORATION OF THE COMPANY, AS AMENDED, AND THE RESOLUTIONS OF THE BOARD OF DIRECTORS OF THE COMPANY, AND THE AUTHORITY OF THE BOARD OF DIRECTORS TO
DETERMINE VARIATIONS FOR FUTURE SERIES. SUCH REQUEST MAY BE MADE TO THE OFFICE OF THE SECRETARY OF THE COMPANY OR TO THE TRANSFER AGENT. THE BOARD OF DIRECTORS MAY REQUIRE THE OWNER OF A LOST OR DESTROYED STOCK CERTIFICATE, OR HIS LEGAL
REPRESENTATIVES, TO GIVE THE COMPANY A BOND TO INDEMNIFY IT AND ITS TRANSFER AGENTS AND REGISTRARS AGAINST ANY CLAIM THAT MAY BE MADE AGAINST THEM ON ACCOUNT OF THE ALLEGED LOSS OR DESTRUCTION OF ANY SUCH CERTIFICATE. The following abbreviations,
when used in the inscription on the face of this certificate, shall be construed as though they were written out in full according to applicable laws or regulations: TEN COM—as tenants in common UNIF GIFT MIN ACT -.Custodian (Cust) (Minor) TEN
ENT - as tenants by the entireties under Uniform Gifts to Minors Act (State) JT TEN —as joint tenants with right of survivorship UNIFâ€^TRF MIN ACT Custodian (until age ) and not as tenants in common (Cust) .under Uniform Transfers
to Minors Act (Minor) (State) Additional abbreviations may also be used though not in the above list. PLEASE INSERT SOCIAL SECURITY OR OTHER IDENTIFYING NUMBER OF ASSIGNEE For value received,hereby sell, assign and transfer unto (PLEASE PRINT OR
TYPEWRITE NAME AND ADDRESS, INCLUDING POSTAL ZIP CODE, OF ASSIGNEE) Shares of the common stock represented by the within Certificate, and do hereby irrevocably constitute and appoint Attorney to transfer the said stock on the books of the
within-named Company with full power of substitution in the premises. Dated: 20 Signature: Signature: Notice: The signature to this assignment must correspond with the name as written upon the face of the certificate, in every particular, without
alteration or enlargement, or any change whatever. Signature(s) Guaranteed: Medallion Guarantee Stamp THE SIGNATURE(S) SHOULD BE GUARANTEED BY AN ELIGIBLE GUARANTOR INSTITUTION (Banks, Stockbrokers, Savings and Loan Associations and Credit Unions)
WITH MEMBERSHIP IN AN APPROVED SIGNATURE GUARANTEE MEDALLION PROGRAM, PURSUANT TO S.E.C. RULE 17Ad-15. The IRS requires that the named transfer agent (“we”) report the cost basis of certain shares or
units acquired after January 1, 2011. If your shares or units are covered by the legislation, and you requested to sell or transfer the shares or units using a specific cost basis calculation method, then we have processed as you requested. If
you did not specify a cost basis calculation method, then we have defaulted to the first in, first out (FIFO) method. Please consult your tax advisor if you need additional information about cost basis. If you do not keep in contact with the issuer
or do not have any activity in your account for the time period specified by state law, your property may become subject to state unclaimed property laws and transferred to the appropriate state.EX-4.3

 Exhibit 4.3 

THIS WARRANT AND THE UNDERLYING SECURITIES AND THE SECURITIES, IF ANY, ISSUABLE UPON THE CONVERSION OF SUCH SECURITIES HAVE NOT BEEN REGISTERED UNDER THE
SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), OR UNDER THE SECURITIES LAWS OF ANY STATE. THESE SECURITIES MAY NOT BE OFFERED, SOLD OR OTHERWISE TRANSFERRED, PLEDGED OR HYPOTHECATED EXCEPT AS PERMITTED UNDER THE ACT AND
APPLICABLE STATE SECURITIES LAWS PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT OR AN EXEMPTION THEREFROM. THE ISSUER OF THESE SECURITIES MAY REQUIRE AN OPINION OF COUNSEL REASONABLY SATISFACTORY TO THE ISSUER THAT SUCH OFFER, SALE OR TRANSFER,
PLEDGE OR HYPOTHECATION OTHERWISE COMPLIES WITH THE ACT AND ANY APPLICABLE STATE SECURITIES LAWS. 
 ASET THERAPEUTICS, INC. 

WARRANT TO PURCHASE STOCK 
  

			
	No. W-1	  	September 21, 2016

 For value received, this Warrant is issued to Roche Finance Ltd (“Holder”) and
entitles Holder to subscribe for and purchase at the Exercise Price (as defined below) from ASET Therapeutics, Inc., a Delaware corporation (the “Company”), the Exercise Shares (as defined below) upon the terms and subject to the
adjustments as provided herein. This Warrant is one of a series of similar Warrants (collectively, the “Warrants”) issued pursuant to that certain Note and Warrant Purchase Agreement, dated as of the date hereof and executed by
Holder and the Purchasers identified on Schedule I attached thereto (the “Purchase Agreement”). 

1.    Definitions. As used herein, the following terms shall have the following respective meanings: 

(a)    “Change of Control” means the occurrence of(i) any transaction or series of related
transactions that results in a “person” or “group” (within the meaning of Section 13(d) and 14(d) of the Securities Exchange Act of 1934, as amended), becoming the “beneficial owner” (as defined in Rule 13d-3 under the Securities Exchange Act of 1934, as amended), directly or indirectly, of more than fifty percent (50%) of the outstanding voting securities of the Company having the right to vote for the election of
members of the Board of Directors of the Company, (ii) any reorganization, merger or consolidation of the Company, other than a transaction or series of related transactions in which the holders of the voting securities of the Company
outstanding immediately prior to such transaction or series of related transactions retain, immediately after such transaction or series of related transactions, at least a majority of the total voting power represented by the outstanding voting
securities of the Company or such other surviving or resulting entity or (iii) a sale, lease or other disposition of all or substantially all of the assets of the Company. 

(b)    “Exercise Period” means the time period commencing on the date hereof and ending on the
earlier to occur of (i) immediately prior to a Change of Control or (ii) the tenth (10th) anniversary of the date hereof. 

  
 1 

 (c)    “Exercise Price” means the price per
share of Qualified Financing Securities paid by the cash investors in a Qualified Equity Financing, subject to adjustment as provided in Section 3. 

(d)    “Exercise Shares” means such number of Warrant Shares equal to the number of Qualified
Financing Securities issued to the Holder upon conversion of such Holder’s Note(s) multiplied by five percent (5%). 

(e)    “Holders” means (as the context requires) more than one of the holders of the Warrants or
all of the holders of the Warrants collectively. 
 (f)    “Notes” means the Convertible
Promissory Notes issued pursuant to the Purchase Agreement. 
 (g)    “Preferred Stock” means
preferred stock of the Company. 
 (h)    “Qualified Equity Financing” has the meaning given
such term Section 5 of the Notes. 
 (i)    “Qualified Financing Securities” means shares
of the same series of Preferred Stock issued in a Qualified Equity Financing. 
 (j)    “Requisite
Holders” has the meaning set forth in the Notes. 
 (k)    “Warrant Shares” means
shares of Qualified Financing Securities. 
 Any capitalized term used but not defined herein shall have the meaning assigned to such term in or by
reference in the Purchase Agreement. 
 2.    Exercise of Warrant. 

2.1    Cash Exercise. The rights represented by this Warrant may be exercised in whole or in part at any time
during the Exercise Period, by delivery of the following to the Company at its address set forth in Section 8(g) of the Purchase Agreement (or at such other address as the Company may designate in writing to the Holder): 

(a)    an executed Notice of Exercise in the form attached hereto as Exhibit A; 

(b)    payment equal to the Exercise Price multiplied by the number of Exercise Shares for which the Warrant is
being exercised; and 
 (c)    this Warrant. 

Upon the exercise of the rights represented by this Warrant, a certificate or certificates for the Exercise Shares so purchased, registered in
the name of the Holder shall be issued and delivered to the Holder as soon as practicable after the rights represented by this Warrant shall have been so exercised. The person in whose name any certificate or certificates for Exercise Shares are to
be issued upon exercise of this Warrant shall be deemed to have become 

  
 2 

 
the holder of record of such shares on the date on which this Warrant was surrendered and payment of the Exercise Price was made, irrespective of the date of delivery of such certificate or
certificates, except that, if the date of such surrender and payment is a date when the stock transfer books of the Company are closed, such person shall be deemed to have become the holder of such shares at the close of business on the next
succeeding date on which the stock transfer books are open. 
 2.2    Net Exercise. Notwithstanding any
provisions herein to the contrary, if the fair market value of one share of the class and series of the Company’s capital stock to which the Exercise Shares belong (the “Stock”) is greater than the Exercise Price (at the date
of calculation as set forth below), in lieu of exercising this Warrant by payment of pursuant to Section 2.1(b) above, the Holder may elect to receive shares equal to the value (as determined below) of this Warrant (or the
portion thereof being canceled) by surrender of this Warrant at the principal office of the Company together with the properly endorsed Notice of Exercise, in which event the Company shall issue to the Holder a number of shares of the applicable
class and series of Stock computed using the following formula: 
  

					
	X = 	 	Y (A – B)	  	
	 	A	  	

  

					
		 	Where X =	  	the number of shares of Stock to be issued to the Holder
			
		 	Y =	  	the number of shares of Stock then purchasable under the Warrant
			
		 	A =	  	the fair market value of one share of the Stock as determined in accordance with Section 2.3 below (at the date of such calculation)
			
		 	B =	  	Exercise Price (as adjusted to the date of such calculation)

 2.3    Determination of Fair Market Value. For purposes of this Warrant, the
fair market value of one share of the Stock shall be determined by the Company’s Board of Directors in good faith as of the date of such calculation; provided, however, that: 

(a)    in the event that this Warrant is exercised pursuant to this Section 2.2 in
connection with the Company’s initial public offering (the “IPO”) of the Company’s Common Stock, the fair market value per share shall be the price per share of the Common Stock sold in such IPO multiplied by the number of
shares of Common Stock into which a share of the Stock may be converted; 
 (b)    in the event that this Warrant
is exercised pursuant to this Section 2.2 following the IPO, the fair market value per share shall be the number of shares of Common Stock into which a share of Stock may be converted multiplied by the fair market value per
share of the Common Stock, which shall be (i) if such Common Stock is traded on a securities exchange or through the Nasdaq National Market, the average of the closing prices of the Common Stock on such exchange or quotation system over the 10
day trading period ending three days prior to the exercise of the Warrant; (ii) if such Common Stock is actively traded over-the-counter, the value shall be deemed
to be the average of the closing bid or sale prices (whichever is applicable) over the 10 day trading period ending three days prior to the exercise of the Warrant; and (iii) if there is no active public market, the value shall be the fair
market value thereof, as determined by the Company’s Board of Directors in good faith; and 

  
 3 

 (c)    in the event that this Warrant is exercised pursuant to
this Section 2.2 in connection with a Change of Control of the Company, the fair market value per share of Stock shall be the price paid for such share of Stock (in cash or in property, as determined by the Company’s
Board of Directors) in connection with the Change of Control. 
 3.    Adjustment of Exercise Price and Exercise
Shares. 
 3.1    Changes in Class and Series of Capital Stock. In the event of
changes in the applicable class and series of the outstanding Stock by reason of stock dividends, splits, recapitalizations, reclassifications, mergers, combinations or exchanges of shares, separations, reorganizations, liquidations, or the like,
the number and class of shares available under the Warrant in the aggregate and the Exercise Price shall be correspondingly adjusted to give the Holder of the Warrant, on exercise for the same aggregate Exercise Price, the total number, class, and
kind of shares as the Holder would have owned had the Warrant been exercised prior to the event and had the Holder continued to hold such shares until after the event requiring adjustment. This Warrant need not be amended because of any adjustment
in the number of Exercise Shares subject to this Warrant. 
 3.2    Certain Events. If at any time after
the date of issuance of this Warrant there is an adjustment to the conversion price of any of the Company’s Preferred Stock pursuant to the Company’s charter then in effect, or if no Preferred Stock is then outstanding, there would have
been an adjustment if any such shares were outstanding, then the Warrant Shares issued upon exercise of this Warrant shall receive the benefit of any such adjustment to its conversion price (to the extent exercisable for any series of Preferred
Stock for which any adjustment to the conversion price has or would have been effected prior to exercise) upon the execution of this Warrant as if the holder thereof held the Warrant Shares issued upon exercise of this Warrant at the time of such
adjustment. In case the Company at any time or from time to time, after the issuance of this Warrant but prior to the exercise hereof, shall take any action affecting its Preferred Stock similar to or having an effect similar to any of the actions
described in Section 3.1 (but not including any action described therein) and the Company’s Board of Directors in good faith determines that it would be equitable in the circumstances to adjust the Exercise Price and
the aggregate number of Warrant Shares for which this Warrant is exercisable as a result of such action, then, and in each such case, the Exercise Price and the aggregate number of Warrant Shares for which this Warrant is exercisable shall be
adjusted in such manner and at such time as the Company’s Board of Directors in good faith determines would be equitable in the circumstances. 

4.    Fractional Shares; Effect of Exercise. No fractional shares shall be issued upon the exercise of this
Warrant. In lieu of issuance of any fractional share to the Holder upon exercise of this Warrant, the Company shall pay to the Holder otherwise entitled to such fraction a sum in cash equal to the product obtained by multiplying the applicable
Exercise Price by such fraction. Upon exercise of this Warrant, the Company shall be forever released from all its obligations and liabilities under this Warrant and this Warrant shall be deemed of no further force or effect, whether or not the
original of this Warrant has been surrendered to the Company pursuant to Section 2 hereof. 

  
 4 

 5.    No Stockholder Rights. This Warrant shall not
entitle the Holder to any right to receive dividends, voting rights or other rights as a stockholder of the Company. 

6.    Lost, Stolen, Mutilated or Destroyed Warrant. The Company covenants to the Holder hereof that, upon
receipt of evidence reasonably satisfactory to the Company of the loss, theft, destruction or mutilation of this Warrant or any stock certificate and, in the case of any such loss, theft or destruction, upon receipt of an indemnity reasonably
satisfactory to the Company, or in the case of any such mutilation, upon surrender and cancellation of such Warrant or stock certificate, the Company shall make and deliver a new Warrant or stock certificate, of like tenor, in lieu of the lost,
stolen, destroyed or mutilated Warrant or stock certificate. 
 7.    Notices. Any notice required or
permitted under this Warrant shall be given in accordance with Section 8(g) of the Purchase Agreement. 

8.    Acceptance. Receipt of this Warrant by the Holder shall constitute acceptance of and agreement to all
of the terms and conditions contained herein. 
 9.    Amendment and Waiver. Any provision of this Warrant
may be amended or waived in a writing signed by both the Company and the Requisite Holders and such amendment or waiver shall be binding on all Holders. 

10.    Governing Law. This Warrant shall be governed by, and construed and enforced in accordance with, the
laws of the State of Delaware, excluding its internal rules governing the conflict of laws. 
 [Signature Page Follows] 

  
 5 

 IN WITNESS WHEREOF, the Company has caused this Warrant to be executed by its duly
authorized officer as of the date first above written. 
  

			
	COMPANY:
	
	ASET THERAPEUTICS, INC.
		
	By:	 	 /s/ David Epstein

		 	David Epstein
		 	Chief Executive Officer

 Accepted: 
 HOLDER

 Roche Finance Ltd 
  

			
	By:	 	 /s/ Beat Kraehenmann

	Name:	 	Beat Kraehenmann
	Title:	 	Authorized Signatory

 Date: 
  

			
	By:	 	 /s/ Andreas Knierzinger

	Name:	 	Andreas Knierzinger
	Title:	 	Authorized Signatory

 Date: 

  
 Signature Page –
ASET Therapeutics, Inc. Warrant 

 EXHIBIT A 

NOTICE OF EXERCISE 
 TO: ASET
Therapeutics, Inc. 
 (1)    ☐ The undersigned hereby elects to purchase
                 shares of                  of ASET Therapeutics, Inc. (the
“Company”) pursuant to the terms of the attached Warrant, and tenders herewith payment of the Exercise Price in full, together with all applicable transfer taxes, if any by; Check all that apply: 

(a)    ☐ payment of US$
                 by wire transfer, federal reference number
                    , 

(b)    ☐ The undersigned hereby elects to purchase
                 shares of                  of the Company pursuant to the
terms of the net exercise provisions set forth in Section 2.2 of the attached Warrant, and shall tender payment of all applicable transfer taxes, if any. 

(2)    Please issue a certificate or certificates representing said shares of Stock in the name of the undersigned or in
such other name as is specified below: 
  
  

Holder 
  

 
 Address 

(3)    The undersigned represents that (i) the aforesaid shares of Stock are being acquired for the account of the
undersigned for investment and not with a view to, or for resale in connection with, the distribution thereof and that the undersigned has no present intention of distributing or reselling such shares; (ii) the undersigned is aware of the
Company’s business affairs and financial condition and has acquired sufficient information about the Company to reach an informed and knowledgeable decision regarding the undersigned’s investment in the Company; (iii) the undersigned
is experienced in making investments of this type and has such knowledge and background in financial and business matters that the undersigned is capable of evaluating the merits and risks of this investment and protecting the undersigned’s own
interests; (iv) the undersigned understands that the shares of Stock issuable upon exercise of this Warrant have not been registered under the Securities Act, by reason of a specific exemption from the registration provisions of the Securities
Act, which exemption depends upon, among other things, the bona fide nature of the investment intent as expressed herein, and, because such securities have not been registered under the Securities Act, they must be held indefinitely unless
subsequently registered under the Securities Act or an exemption from such registration is available; (v) the undersigned is aware that the aforesaid shares of Stock may not be sold pursuant to Rule 144 adopted under the Securities Act unless
certain conditions are met and until the undersigned has held the shares for the number of years prescribed by Rule 144, that among the conditions for use of the Rule is the availability of current information to the public about the Company and the
Company has not made such information available and has no present plans to do so; (vi) the undersigned is an “accredited 

  
 Exhibit A-1 

 
investor” (as defined in Rule 501 promulgated pursuant to the Securities Act); and (vii) the undersigned agrees not to make any disposition of all or any part of the aforesaid shares of
Stock unless and until there is then in effect a registration statement under the Securities Act covering such proposed disposition and such disposition is made in accordance with said registration statement, or the undersigned has provided the
Company with an opinion of counsel satisfactory to the Company, stating that such registration is not required. 
  

					
	  
 Date
	  		  	  
 (Signature)

			
		  		  	  
 (Signature)

  
 Exhibit A-2

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00303-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00303-of-00352.parquet"}]]